Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1016)	8/25/2000 10:46:08 PM
From: Londo	Respond to of 1298

Hi, This analyst did not do his homework. Although he acknowledged that the low P/E came from investment gains, generally speaking it should not be a criteria to buy a stock, since such gains are already absolutely priced in. No other comments.

To: tuck who wrote (1016)	8/26/2000 3:19:03 AM
From: Bosco	Read Replies (2) \| Respond to of 1298

Hi all - Ms Joan Lappin of Gramercy Capital mentioned CEGE on NBR nightlybusiness.org [note: it is a current transcript as I write, but for future reference, it is the 8/25/2000 transcript.] although it was misspelled as "Cell Genesis" in the transcript. I was watching the show and was quite surprised when she mentioned the name, since her outfit is more into concentrated portfolio and her themes are tech [MOT,] biotech [CEGE,] financial [LEH,] and excellent mgt [C,] one would think she would stick to a big name biotech. On a separate note, technically, CEGE seems to hang in there by closing above 28. Maybe this bit of exposure will help to put the floor down for a real launch :) best, Bosco